Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Myles O'Neill Biography and Net Worth

SVP of Eli Lilly and Company

Myles O’Neill is senior vice president and president of Manufacturing Operations for Eli Lilly and Company.

He served as senior vice president of global parenteral drug product, delivery devices and regional manufacturing from 2012 until 2017. In this role, Myles was responsible for global parenteral manufacturing, emerging markets manufacturing, drug-product contract manufacturing, packaging and distribution operations. He provided oversight for manufacturing sites in 12 countries throughout North America, South America, Europe and Asia; these sites manufacture our final parenteral products that reach patients.

Myles has worked extensively in the pharmaceutical industry, including roles at Pfizer and other major companies. His Lilly career began in 2002, when he became director of bulk pharmaceutical operations. In 2005, Myles became vice president of Indianapolis parenteral operations.

He holds a bachelor’s degree in chemistry from University College Cork in Cork, Ireland, and a master’s degree in business administration through DCU, Dublin. Myles is known for his strong leadership and expertise in Good Manufacturing Practices and FDA-approved pharmaceutical manufacturing environments.

What is Myles O'Neill's net worth?: The estimated net worth of Myles O'Neill is at least $33.41 million as of March 4th, 2020. Mr. O'Neill owns 44,773 shares of Eli Lilly and Company stock worth more than $33,409,613 as of November 18th. This net worth approximation does not reflect any other investments that Mr. O'Neill may own. Learn More about Myles O'Neill's net worth.
How do I contact Myles O'Neill?: The corporate mailing address for Mr. O'Neill and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Myles O'Neill's contact information.
Has Myles O'Neill been buying or selling shares of Eli Lilly and Company?: Myles O'Neill has not been actively trading shares of Eli Lilly and Company within the last three months. Most recently, Myles O'neill sold 25,000 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a transaction totalling $3,503,750.00. Following the completion of the sale, the senior vice president now directly owns 44,773 shares of the company's stock, valued at $6,274,935.95. Learn More on Myles O'Neill's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Myles O'Neill Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2020	Sell	25,000	$140.15	$3,503,750.00	44,773
12/6/2019	Sell	25,000	$120.00	$3,000,000.00	40,424
12/10/2018	Sell	25,000	$112.92	$2,823,000.00	26,562

Myles O'Neill Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $737.00

$737.00

50 Day Range

MA: $882.65

$745.89

$935.09

2 Week Range

Now: $737.00

$561.65

$972.53

Volume

44,770 shs

Average Volume

3,124,268 shs

Market Capitalization

$699.65 billion

P/E Ratio

79.68

Dividend Yield

0.70%

Beta

0.43

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide